Despite Pluvicto ghosting everyone since March, PSMA PET is becoming an increasingly important part of the management of prostate cancer. PSMA PET appears more sensitive at detecting metastases than its rival fluciclovine. However, PSMA PET currently relies on the radioisotope Ga68. This randomized cross-over trial demonstrates the non-inferiority of F18-PSMA. In fact, F18-PSMA detected a few more lesions than Ga68-PSMA. Compared to Ga68 radiotracers, F18 radiotracers have higher positron yield, a longer half-life, and a production process that may provide more widespread access to PSMA PET. In addition, the lower positron energy of F18 may provide better spatial resolution.
- De Man, Eur Urol 2022